RAI-R DTC
Oncology · 2016–2016
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| lenvatinib Treatment of radioactive iodine refractory differentiated thyroid cancer (RR-DTC), specifically patients with locally advanced or metastatic disease. | Mar 2016 | Not recommended | input received Medical Oncology Group |
Who spoke
Medical Oncology Group
What the PBS pays
$31M in government benefit over 2024–25, across 8,151 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| lenvatinib | $31.4M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.